Skip to main content
Smart Investors Daily
SI

NASDAQ · SIBN

SI-BONE, Inc.

Healthcare · Medical - Devices

$23.41

Down-$0.03 (-0.13%)

Updated Nov 17, 2026, 11:47 AM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
816.58M
P/E ratio
-33.89
Dividend yield
0.00%
52-week range
$11.48 – $25.92
Volume
600K
Avg. volume
529.81K

Price performance · SIBN

SIBN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

SIBN closed at $23.41 after 21 trading sessions, up 19.07% for the selected period.

Last close
$23.41
Period change
+19.07%
Period low
$19.66
Period high
$25.60
Daily close
View OHLC price history
SIBN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$23.37$23.665$23.0902$23.41600K
Nov 13, 2026$24.40$24.68$23.40$23.44443.69K
Nov 12, 2026$24.88$25.07$24.00$24.14744.28K
Nov 11, 2026$25.10$25.47$24.72$24.94547.42K
Nov 10, 2026$25.47$25.70$24.85$25.10745.27K
Nov 9, 2026$24.21$25.74$23.3901$25.601.44M
Nov 6, 2026$23.67$24.53$23.55$24.24683.47K
Nov 5, 2026$24.95$25.02$23.66$24.27924.94K
Nov 4, 2026$24.00$25.9201$23.8805$24.952.19M
Nov 3, 2026$19.50$23.93$19.07$23.773.3M
Nov 2, 2026$21.57$21.99$20.19$20.221.37M
Oct 30, 2026$22.25$22.25$20.95$21.231.25M
Oct 29, 2026$22.00$22.95$21.83$22.41950.31K
Oct 28, 2026$21.32$21.96$21.32$21.83452.49K
Oct 27, 2026$21.40$21.63$21.11$21.44482.18K
Oct 26, 2026$21.41$21.5599$20.70$21.31361.06K
Oct 23, 2026$21.21$21.63$20.665$21.48469.09K
Oct 22, 2026$20.93$21.73$20.93$21.56527.76K
Oct 21, 2026$20.35$21.22$20.275$20.82812.81K
Oct 20, 2026$19.90$20.59$19.85$20.54640.8K
Oct 19, 2026$19.38$19.92$19.38$19.66338.15K

Latest SIBN news

The latest Smart Investors Daily articles mentioning SIBN.

SIBN research

Overview

Company profile and research snapshot.

Company profile

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.67
Implied upside
—
Analysts
—
SIBN recent ratings
DateFirmRatingTarget
Nov 3, 2026TD CowenBuy—
Nov 3, 2026UBSBuy—
Nov 3, 2026NeedhamBuy—
Oct 14, 2026Truist SecuritiesBuy—
Aug 4, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

SI-BONE (SIBN) Stock Rallies As Q3 Results Sharpen Profit Focus

SI-BONE stock ripped higher, closing at US$23.77, up 17.6% on the first full trading day after its Q3 2026 report. Traders focused on the headline beat in procedure activity and adjusted EBITDA, rather than on the fact the business is still posting a net loss of US$3.6 million for the quarter. For a medtech growth story, the real hook is the profit trend. Revenue reached US$55.7 million in Q3, and trailing twelve month losses have been steadily shrinking. In the short term, the chart grabbed...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.